CELLULAR AND HUMORAL IMMUNOGENICITY OF DIFFERENT FORMULATIONS BASED ON RECOMINANT TRANSIALIDASES FOR THE DEVELOPMENT OF A MUCOSAL VACCINE AGAINST T. cruzi

PACINI MF.; GONZÁLEZ FB; BULFONI BALBI C; PÉREZ AR

San Miguel de Tucumán

Congreso; LXVII Reunión Científica Anual de la Sociedad Argentina de Inmunología; 2019

Sociedad Argentina de Inmunología

Currently, there are no prophylactic vaccines to fight Chagas disease. Some antigens derivedfrom parasite Transialidase (TS) family have shown promising results as vaccine candidates inmouse models. Here, we evaluated the immunogenicity of different fragments of recombinantTS (TSNt and TSCt), pooled or not. TS fragments were selected by bioinformatics, coveringdifferent regions containing B and T epitopes, some of them immunodominant. Vaccineformulations comprised such recombinant TS with adjuvants (c-di-AMP or ISPA). Theseformulations were used to immunize BALB/c mice (n=5-6/group) intranasally (three doses, oneevery two weeks). As controls, groups of mice were treated with PBS (non-immunized) or withTS fragments, c-di-AMP or ISPA alone. Fifteen days after the last immunization, cell-mediatedimmunity was evaluated in vivo (delayed hypersensitivity test-DHT) and in vitro (flowcytometry). Specific humoral immunity was also measured (ELISA). Results indicated thatimmunized groups TSNt+ISPA, TSCt+ISPA, TSNt+c-di-AMP, TSCt+c-di-AMP, TS(Nt+Ct)+ISPA andTS(Nt+Ct)+c-di-AMP generated an increased cellular response by DHT after 24 and 48 hourscompared with control groups (p